查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870478

细菌性阴道炎治疗市场按药物类别、给药途径、剂型、通路和最终用户划分－2025-2032年全球预测

Bacterial Vaginosis Drugs Market by Drug Class, Route Of Administration, Dosage Form, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细菌性阴道炎治疗市场将成长至 14.8067 亿美元，复合年增长率为 6.10%。

关键市场统计数据
基准年 2024 9.2192亿美元
预计年份：2025年 9.794亿美元
预测年份 2032 14.8067亿美元
复合年增长率 (%) 6.10%

本书简明扼要地介绍了当代细菌性阴道炎治疗领域在临床、微生物学和以患者为中心的挑战。

细菌性阴道炎仍然是临床实践中最常见的阴道疾病之一，其复杂的微生物学特征和多样化的症状给临床医生和患者都带来了持续的挑战。虽然传统的抗生素疗法能够为许多患者缓解症状，但频繁的復发、患者反应的差异以及宿主免疫与阴道微生物群之间的相互作用，都凸显了开发更精细化治疗方法的必要性。因此，研究、临床和商业领域的相关人员越来越关注那些能够平衡疗效和耐受性并显着降低復发率的干预措施。

重新定义细菌性阴道炎的治疗模式，定义治疗创新、诊断技术、数位化护理路径和监管演变的变革性变化

细菌性阴道炎的治疗模式正因技术、监管和临床方面的进步而重塑，这些进步加速了预防和治疗新方法的出现。以微生物组为导向的策略和生物治疗产品，以及重新设计的抗菌药物和标靶给药系统相继问世，可望降低復发率并提高耐受性。同时，诊断技术日益精细化和普及，能够更早、更准确地区分肠道菌丛失调和其他导致阴道炎的因素。这使得处方笺更加精准，并减少了经验性抗生素的使用。

分析2025年实施的累积关税如何改变了阴道治疗药物及相关製造活动的供应链策略、采购决策和商业运营

2025年的关税调整为阴道治疗药物的供应链和商业营运带来了新的策略考量。从国际供应商购买活性药物成分、辅料和特殊包装的成本压力和监管审查日益加剧，迫使许多製造商和合约合作伙伴重新评估其供应商组合和库存策略。为此，各公司正优先发展双重采购安排、实现供应商地域多元化，并提高上游工程透明度，以降低贸易政策波动带来的风险，并维持供应的连续性。

从富有洞察力的细分观点，将治疗领域、给药途径、製剂选择、分销管道和终端用户环境与临床应用和商业策略联繫起来。

细分市场分析揭示了不同治疗领域、给药途径、剂型、分销管道和终端用户之间存在的显着差异，这些差异会影响临床应用和商业性策略。依药物类别划分，市场可分为抗生素和消毒剂，其中抗生素可细分为克林霉素、甲硝唑和替硝唑。每类药物都具有独特的疗效特征、抗药性考量和製剂开发机会，这些都会影响处方模式。依给药途径划分，市场可分为口服和阴道给药。口服疗法往往着重于全身性用药的便利性，而阴道给药则优先考虑局部暴露和减少全身性副作用。依剂型划分，市场可分为乳膏剂、凝胶剂、栓剂和片剂，剂型的选择直接影响患者依从性、药物动力学和生产复杂性。例如，与口服片剂相比，黏膜黏附凝胶和栓剂可能在局部浓度较高、全身吸收较低的情况下达到更高的药物浓度。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 扩大靶向益生菌阴道栓剂的使用范围，以预防细菌性阴道炎復发
  • 增加对非抗生素生物膜破坏剂的研发投入，用于治疗方法细菌性阴道炎
  • 监管加速核准将加速新型细菌性阴道炎治疗方法的临床应用
  • 生技Start-Ups与製药巨头建立策略伙伴关係，推动细菌性阴道炎治疗产品线的扩展。
  • 快速诊断检测技术的进步使得在护理现场即可製定个人化的细菌性阴道炎治疗方案成为可能。
  • 阴道微生物群对抗生素的抗药性增加，推动了对替代性细菌性阴道炎疗法的需求。
  • 一种长效型阴道栓剂的出现，该栓剂结合了抗菌剂和抗发炎剂，用于预防细菌性阴道炎。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依药物类别分類的细菌性阴道炎治疗市场

  • 抗生素
    • 克林霉素
    • 甲硝唑
    • 替硝唑
  • 消毒剂

9. 依给药途径分類的细菌性阴道炎治疗市场

  • 口服
  • 阴道给药

第十章：以剂型分類的细菌性阴道炎治疗市场

  • 奶油
  • 凝胶
  • 栓剂
  • 药片

第十一章 细菌性阴道炎治疗市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终使用者分類的细菌性阴道炎治疗市场

  • 诊所
  • 家庭医疗保健
  • 医院

第十三章 各地区细菌性阴道炎治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的细菌性阴道炎治疗市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国细菌性阴道炎治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Sandoz Inc.
    • Viatris Inc.
    • Dr. Reddy's Laboratories Ltd
    • Lupin Limited
    • Cipla Limited
    • Perrigo Company plc
    • Gedeon Richter Plc
    • Glenmark Pharmaceuticals Limited
Product Code: MRR-1A1A064C0104

The Bacterial Vaginosis Drugs Market is projected to grow by USD 1,480.67 million at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 921.92 million
Estimated Year [2025] USD 979.40 million
Forecast Year [2032] USD 1,480.67 million
CAGR (%) 6.10%

A concise but sweeping introduction to the clinical, microbiological, and patient-centric challenges that define the contemporary therapeutic landscape for bacterial vaginosis

Bacterial vaginosis remains one of the most commonly diagnosed vaginal conditions encountered in clinical practice, and its complex microbiology and symptom variability create persistent challenges for clinicians and patients alike. While classical antibiotic regimens have provided symptomatic relief for many, recurrent episodes, heterogeneous patient responses, and the interplay between host immunity and the vaginal microbiome have underscored the need for a more nuanced therapeutic approach. Consequently, stakeholders across the research, clinical, and commercial spectrum are increasingly focused on interventions that balance efficacy with tolerability and that meaningfully reduce recurrence.

Over the past decade, diagnostic refinement and a deeper understanding of dysbiosis have shifted attention toward therapies that preserve or restore microbiome balance while targeting pathogenic overgrowth. In parallel, patient expectations have evolved: adherence, convenience, and formulation tolerability are now central determinants of therapy selection. These clinical and patient-centered drivers, combined with heightened scrutiny around antimicrobial stewardship, create a dynamic environment in which innovation, regulatory alignment, and supply chain resilience jointly determine which therapeutic strategies will gain sustained adoption.

Defining the transformative shifts across therapeutic innovation, diagnostics, digital care pathways, and regulatory evolution that are redefining bacterial vaginosis treatment paradigms

The landscape for bacterial vaginosis therapeutics is being reshaped by intersecting technological, regulatory, and clinical advances that are accelerating new approaches to prevention and treatment. Microbiome-directed strategies and live biotherapeutic products are emerging alongside reformulated antimicrobials and targeted delivery systems, offering potential to reduce recurrences and improve tolerability. Diagnostics are simultaneously becoming more granular and accessible, enabling earlier, more accurate differentiation between dysbiosis and other causes of vaginitis, which in turn informs precision prescribing and reduces empirical antibiotic use.

Digital health and telemedicine channels have expanded care pathways, allowing for remote triage, adherence monitoring, and iterative patient education that improve outcomes, especially for populations with limited clinic access. Regulatory frameworks are evolving to accommodate novel modalities, while payers and formulary committees are placing greater emphasis on real-world effectiveness and value-based contracting. Together, these shifts are changing competitive dynamics: companies that integrate advanced diagnostics, patient-centric formulations, and robust post-market evidence will be positioned to lead adoption and to shape standard-of-care pathways.

Analyzing how the cumulative tariff measures enacted in 2025 have altered supply chain strategies, sourcing decisions, and commercial operations for vaginal therapeutics and related manufacturing activities

The tariff adjustments implemented in 2025 have introduced a new set of strategic considerations for supply chain and commercial operations that support vaginal therapeutics. Sourcing of active pharmaceutical ingredients, excipients, and specialized packaging from international suppliers is subject to elevated cost pressures and regulatory scrutiny, prompting many manufacturers and contract partners to reassess supplier portfolios and inventory strategies. In response, firms are prioritizing dual-sourcing arrangements, regional supplier diversification, and increased transparency across upstream tiers to reduce exposure to trade policy volatility and to maintain continuity of supply.

Beyond procurement, the tariff environment has influenced decisions around domestic manufacturing investment and nearshoring of critical production capabilities. Companies evaluating capital allocation are weighing the trade-offs between higher fixed costs associated with localized production and the resilience benefits of shorter supply chains. At the commercial level, distributors and pharmacies are recalibrating purchasing rhythms and negotiating terms to preserve margins while minimizing disruption for clinicians and patients. Importantly, these shifts have also accelerated collaborations between manufacturers and logistics providers to optimize cross-border flows and to adopt value chain innovations that mitigate the operational impact of sustained tariff regimes.

Insightful segmentation perspectives that connect therapeutic classes, administration routes, formulation choices, distribution channels, and end-user settings to clinical adoption and commercial strategy

Segmentation analysis reveals differentiated dynamics across therapeutic classes, routes of administration, dosage forms, channels, and end users that shape clinical use and commercial prioritization. Based on drug class, the market is studied across antibiotics and antiseptics, with antibiotics further delineated into clindamycin, metronidazole, and tinidazole; each class presents distinct efficacy profiles, resistance considerations, and formulation opportunities that influence prescribing patterns. Based on route of administration, the market is studied across oral and vaginal approaches, where oral therapies often emphasize systemic convenience while vaginal routes prioritize localized exposure and reduced systemic side effects. Based on dosage form, the market is studied across cream, gel, suppository, and tablets, and formulation choice directly affects patient adherence, pharmacokinetics, and manufacturing complexity; for example, mucoadhesive gels and suppositories may deliver higher local concentrations with lower systemic absorption than oral tablets.

Based on distribution channel, the market is studied across hospital pharmacy, online pharmacy, and retail pharmacy, which each carry different reimbursement models, patient access pathways, and logistics considerations; hospital formularies typically emphasize guideline-aligned therapies for acute presentations, while online and retail channels emphasize convenience and chronic management solutions. Based on end user, the market is studied across clinics, home healthcare, and hospitals, and demand drivers vary with care setting: clinics and hospitals prioritize rapid diagnostics and standardized treatment pathways, whereas home healthcare and outpatient settings place greater weight on ease of use and telehealth integration. Collectively, these segmentation lenses inform product development, go-to-market strategies, and evidence generation priorities, and they underscore the necessity of aligning clinical utility with distribution and patient adoption models.

Regional strategic imperatives and differentiated market dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific that drive access, regulation, and commercialization

Regional dynamics exert strong influence on product development priorities, regulatory navigation, and commercial execution in the bacterial vaginosis therapeutic space. Americas markets tend to emphasize rapid uptake of evidence-backed treatments, integration with primary care pathways, and mature reimbursement mechanisms that support both branded and generic options; meanwhile, public health initiatives focused on sexual and reproductive health create opportunities for bundled care models that include diagnostics and adherence support. Europe, Middle East & Africa present a heterogeneous regulatory and payer environment where national formularies and stewardship programs shape therapeutic selection, and where access can be constrained by fragmented procurement practices; partnerships with regional distributors and local clinical opinion leaders frequently prove decisive for adoption.

Asia-Pacific includes large, diverse markets with varying degrees of regulatory sophistication and manufacturing capacity, which creates both risk and opportunity: some countries are increasingly important manufacturing hubs for active pharmaceutical ingredients and finished dosage forms, while others represent fast-growing patient populations with distinct care delivery models. Cross-region collaboration on standards, regulatory harmonization, and clinical trial design can accelerate evidence generation and enable more efficient market entry. Taken together, regional strategies must be tailored to local clinical guidelines, supply chain realities, and payer expectations to maximize both access and therapeutic impact.

Corporate strategic behaviors, alliance models, and innovation pathways among incumbents and emergent biotherapeutic companies that are reshaping competition in bacterial vaginosis care

Competitive intensity in this therapeutic category reflects a mix of established pharmaceutical manufacturers, specialized generics producers, and emerging biotherapeutic firms that are pursuing diverse routes to differentiation. Established manufacturers focus on formulation improvements, lifecycle management, and distribution scale to protect and extend product relevance, while specialists and bioscience startups are advancing innovative modalities, including microbiome therapeutics and targeted delivery systems, to address unmet clinical needs and to reduce recurrence. Collaboration between originators, contract development and manufacturing organisations, and specialty distributors is common, enabling faster scale-up of novel dosage forms and broader geographic reach.

Strategic behaviors to watch include licensing agreements that accelerate access to local markets, value-based partnerships with healthcare providers that link reimbursement to real-world outcomes, and platform investments that enable multiple product candidates to leverage shared manufacturing or analytical capabilities. Intellectual property strategies are increasingly focused on formulation patents, delivery technologies, and companion diagnostics, rather than solely on active ingredient exclusivity. These dynamics underscore the importance of an orchestration mindset: companies that combine scientific differentiation with operational discipline and targeted partnerships are best positioned to capture emerging clinical and commercial opportunities.

Actionable strategic recommendations that combine supply chain resilience, regulatory engagement, patient-centric formulation development, and partnerships to drive sustained competitive advantage

Industry leaders should take an integrated approach that balances near-term operational resilience with long-term innovation investment. First, diversify procurement and qualify alternative suppliers to reduce exposure to trade policy shifts and to enhance continuity of supply for active ingredients and specialized excipients. Simultaneously, evaluate regional manufacturing options where appropriate to improve lead times and to provide strategic hedges against cross-border disruptions. In parallel, prioritise development of patient-centric formulations and delivery systems that improve adherence and reduce recurrence, while building evidence through pragmatic clinical studies and real-world evidence collection to support formulary inclusion and prescriber confidence.

Engage early with regulatory authorities to clarify pathways for novel modalities and to align on trial endpoints that reflect both clinical benefit and patient-reported outcomes. Forge partnerships with diagnostic innovators and digital health providers to create integrated care pathways that enable precision treatment decisions and that support adherence monitoring. Finally, adopt flexible commercial models that accommodate hospital formulary requirements, retail convenience, and online channels, and invest in differentiated value propositions that resonate with payers, clinicians, and patients alike. These steps will help organisations translate scientific advances into durable clinical and commercial impact.

An overview of the mixed-methods research design combining evidence synthesis, primary stakeholder interviews, data triangulation, and scenario validation to underpin strategic conclusions

The research methodology underpinning this analysis combines structured evidence synthesis with primary stakeholder engagement and qualitative validation to ensure robustness and practical relevance. Secondary research involved critical appraisal of peer-reviewed clinical literature, regulatory guidance, and public health policy documents to establish baseline understanding of disease biology, guidelines, and therapeutic modalities. Building on that foundation, targeted interviews were conducted with clinicians, pharmacists, procurement specialists, and industry executives to capture real-world practice patterns, unmet needs, and commercial constraints.

Data triangulation and thematic analysis were applied to integrate insights across sources and to identify consistent trends and divergent viewpoints. Scenario planning exercises explored operational responses to supply chain shocks and regulatory changes, while validation workshops with independent clinical advisors sharpened interpretation of evidence related to treatment effectiveness and patient adherence. Limitations include reliance on available published data and interview sampling frames, which were managed through purposive recruitment and cross-validation to reduce bias and to increase the credibility of the findings.

A synthesized conclusion that ties clinical innovation, supply chain resilience, and commercial execution together as the essential pillars for future success in bacterial vaginosis therapeutics

In aggregate, the therapeutic landscape for bacterial vaginosis is characterized by persistent clinical need, evolving scientific opportunity, and shifting commercial dynamics. Advances in microbiome science and targeted delivery are converging with more accessible diagnostics and digital care models to create pathways for therapies that not only relieve symptoms but also reduce recurrence and improve quality of life. At the same time, trade policy shifts and supply chain pressures highlight the importance of operational resilience and strategic sourcing as prerequisites for reliable patient access.

Looking ahead, organisations that integrate clinical innovation with pragmatic commercial execution-leveraging partnerships, investing in evidence generation, and aligning with local care delivery models-will be best positioned to convert scientific promise into meaningful patient outcomes. The path to impact requires coordinated activity across R&D, regulatory affairs, manufacturing, and commercial teams, informed by a clear understanding of segmentation and regional dynamics to ensure therapeutics meet the needs of clinicians and patients in diverse settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing adoption of targeted probiotic vaginal suppositories to reduce bacterial vaginosis recurrence
  • 5.2. Escalating R&D investment in non-antibiotic biofilm disruptors for BV treatment modalities
  • 5.3. Regulatory fast track approvals accelerating clinical availability of novel BV therapies
  • 5.4. Strategic partnerships between biotech startups and pharma giants driving BV pipeline expansion
  • 5.5. Advancements in rapid diagnostic tests enabling personalized BV drug regimens at point of care
  • 5.6. Rising prevalence of antibiotic-resistant vaginal microbiota fueling demand for alternative BV therapies
  • 5.7. Emergence of long acting vaginal inserts combining antimicrobial and anti inflammatory agents for BV prevention

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bacterial Vaginosis Drugs Market, by Drug Class

  • 8.1. Antibiotics
    • 8.1.1. Clindamycin
    • 8.1.2. Metronidazole
    • 8.1.3. Tinidazole
  • 8.2. Antiseptics

9. Bacterial Vaginosis Drugs Market, by Route Of Administration

  • 9.1. Oral
  • 9.2. Vaginal

10. Bacterial Vaginosis Drugs Market, by Dosage Form

  • 10.1. Cream
  • 10.2. Gel
  • 10.3. Suppository
  • 10.4. Tablets

11. Bacterial Vaginosis Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Bacterial Vaginosis Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Healthcare
  • 12.3. Hospitals

13. Bacterial Vaginosis Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bacterial Vaginosis Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bacterial Vaginosis Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Teva Pharmaceutical Industries Ltd.
    • 16.3.2. Pfizer Inc.
    • 16.3.3. Sandoz Inc.
    • 16.3.4. Viatris Inc.
    • 16.3.5. Dr. Reddy's Laboratories Ltd
    • 16.3.6. Lupin Limited
    • 16.3.7. Cipla Limited
    • 16.3.8. Perrigo Company plc
    • 16.3.9. Gedeon Richter Plc
    • 16.3.10. Glenmark Pharmaceuticals Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BACTERIAL VAGINOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BACTERIAL VAGINOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BACTERIAL VAGINOSIS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINDAMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY METRONIDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TINIDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTISEPTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY VAGINAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CREAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUPPOSITORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 249. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 253. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 254. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 255. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 258. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 259. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 262. GCC BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 294. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 295. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 296. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 297. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 298. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 299. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 300. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 301. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. G7 BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 310. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 311. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 312. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 313. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2018-2024 (USD MILLION)
  • TABLE 314. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DOSAGE FORM, 2025-2032 (USD MILLION)
  • TABLE 315. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 318. NATO BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL BACTERIAL VAGINOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-